What is follicular lymphoma? It is usually a slow-growing B-cell non-Hodgkin lymphoma. NCI definition. Tissue classification and clinical assessment guide observation or treatment.
Confidence: moderate to high for selected diagnostic and safety distinctions. Care pathways are attributed guidance; independent superiority of a medicine or supplement is not established here.
- Keep the complete pathology name and classification system.
- Observation requires a written monitoring plan.
- A prognostic score is not a treatment prescription.
- Changing disease behavior deserves reassessment.
Table of contents
- Evidence summary
- What follicular lymphoma is: an adult B-cell cancer with several separate entities
- Symptoms and investigation: a painless lump is a reason for assessment
- Biopsy and grading: classic FL, grade 3B and WHO versus ICC
- Stage and FLIPI
- Observation and treatment: selected monitoring, local radiation and systemic care
- Relapse and transformation
- Urgent symptoms and treatment harms: infection and severe breathing difficulty
- Nutrition, fertility and supplements: support without an anticancer shortcut
- Follow-up and maintenance: monitoring is a plan and maintenance is treatment
- Research limits: MRD, imaging and trials require the right question
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Classification | WHO; ICC | Publishing support and separate author ties. | Naming only. |
| Clinical care | NCI PDQ; ESMO | Reviewer/author interests; trial receipts unclosed. | No drug ranking. |
| Monitoring | CUH clinic | Own provider revenue; leaflet allocation unknown. | Local pathway only. |
| Support | NCI | Public/gift routes; study finances unclosed. | Symptom support alongside care. |
What follicular lymphoma is: an adult B-cell cancer with several separate entities
Follicular lymphoma is usually an indolent B-cell non-Hodgkin lymphoma. “Follicular” describes groups of tumor cells seen microscopically, not hair follicles. NCI definition.
This guide addresses the common adult classic follicular lymphoma setting. WHO separately recognizes in situ follicular B-cell neoplasm, pediatric-type and duodenal-type disease. WHO family boundary.
A brief mention here does not complete their dedicated guides. Keep the diagnosis exactly as written when requesting further information. Ask the team which classification it used and which part of the report still needs explanation. Do not replace the actual pathology name with a general online lymphoma label.
Symptoms and investigation: a painless lump is a reason for assessment
NHS lymphoma symptoms include a painless neck, armpit or groin lump, night sweats, fever, itching, breathlessness and unexplained weight loss. These can have other causes; urgent referral investigates them rather than confirming cancer. NHS symptoms and referral.
A biopsy establishes the tissue diagnosis. Blood tests, imaging and selected marrow sampling answer further questions about extent and planning. NHS investigation roles.
Tell the clinician which changes are new, how quickly a lump is changing and whether symptoms interrupt sleep or usual activities. Bring earlier reports rather than trying to infer a cancer subtype from a photograph, blood count or internet description. If a specimen is inadequate, ask which service will arrange the next assessment and how its result will be communicated.
Biopsy and grading: classic FL, grade 3B and WHO versus ICC
The dated ESMO guideline favors excisional tissue, using core biopsy when nodes are inaccessible; fine-needle aspiration alone is insufficient for a reliable primary diagnosis. ESMO specimen guidance.
WHO makes classic-FL grading optional and renames former grade 3B largely as follicular large B-cell lymphoma. ICC retains cytologic grading. WHO naming; ICC grading.
This difference is a reason to preserve the classification system, not to invent a grade from a scan. Expert review should explain whether the case belongs to this common indolent scope or a separate large B-cell pathway. The service performing a biopsy supplies preparation and any anticoagulant instructions; this article gives no personal medicine-hold schedule.
Stage and FLIPI
Stage describes extent, while type and grade describe different disease properties. NHS stage and type. These labels should not be treated as interchangeable descriptions.
FLIPI is prognostic; it cannot establish treatment need or predict response. NCI FLIPI limits.
Ask the specialist to explain the actual assessment and its role in the written plan. Keep the results with that explanation so later conversations concern the same findings. This guide supplies no numerical score, tumor-size cutoff or survival prediction and cannot calculate an individual treatment decision.
Observation and treatment: selected monitoring, local radiation and systemic care
For selected slow-growing NHL without symptoms, treatment can sometimes be delayed with planned monitoring. Other care families include chemotherapy, targeted medicines and radiation. NHS low-grade care context.
The dated ESMO framework considers symptoms, impaired blood-cell production, bulky or compressive disease and rapid progression when reviewing treatment. Localized radiation may have curative intent. ESMO selected care context.
Observation is an option, not a rule for every asymptomatic patient or a plan to ignore new problems. Ask whether the proposed care is observation, a local treatment or systemic treatment, why it fits the actual diagnosis, and which alternatives are appropriate in your country. A monitoring appointment and an anticancer infusion are different activities; neither should be mistaken for a personal schedule supplied by this guide.
Relapse and transformation
Rapid or uneven growth can prompt biopsy for suspected transformation, if feasible. Confirmed histology changes care. NCI transformation assessment.
Concern is not the same as confirmation. Contact the treating service about a change rather than assuming that an enlarging node proves transformation or that an old slow-growing label settles a new problem. Keep previous pathology, treatment dates and response reports together so the discussion concerns the actual course.
NHS describes selected targeted, immune and transplant pathways for further NHL treatment. NHS further-care context. Their suitability is individualized; another person’s treatment or an older drug menu cannot establish your eligibility. Before a new plan, clarify which diagnosis is being treated and whether the service needs an updated specimen.
Urgent symptoms and treatment harms: infection and severe breathing difficulty
Possible infection during cancer treatment needs prompt oncology contact; fever-reducing medicines can hide a warning. NCI infection precautions. Follow the service’s emergency instructions, including outside clinic hours, rather than waiting for the next routine visit.
Severe breathing difficulty, inability to speak normally because of breathing, or sudden confusion needs emergency help. NHS emergency signs. Explain the cancer diagnosis and recent treatment when seeking assistance.
Immunotherapy can inflame healthy tissues, with effects during or after treatment. NCI immune-side-effect context. New symptoms should be reported rather than automatically blamed on lymphoma. The actual prescription determines monitoring, prevention and adverse-effect care; this guide does not give an online fluid, steroid, antibiotic or drug-stop protocol. Obtain the urgent contact route before starting a new treatment.
Nutrition, fertility and supplements: support without an anticancer shortcut
Nutrition support differs from claims that a diet or supplement treats cancer. NCI nutrition boundary. Report problems eating or maintaining intake so practical support can be arranged rather than adopting a restrictive anticancer diet.
Food, herbs and supplements can interact with particular cancer medicines. NCI interaction context. Share product labels, including items taken only between treatments. This review establishes no independent supplement control of follicular lymphoma or prevention of transformation.
NCI’s female fertility and male fertility resources describe treatment-dependent reproductive risks. Discuss future parenting before treatment where feasible; preservation options require individual assessment.
Palliative care can accompany disease-directed care for symptoms, emotional concerns and practical support. NCI palliative-care role. Asking for help does not require abandoning anticancer treatment.
Follow-up and maintenance: monitoring is a plan and maintenance is treatment
CUH’s selected maintenance clinic reviews blood results and new symptoms with specialist nurses working alongside consultants. CUH local maintenance pathway. This describes one service, not a universal maintenance medicine or calendar. If treatment or testing is delayed, contact your own team for the next instruction.
CUH describes consultant responsibility, nurse coordination and multidisciplinary discussion of scans and biopsies. CUH team roles. Confirm who explains results, who arranges the next appointment and whom to contact between reviews.
After treatment, NCI advises a written treatment summary and follow-up plan. NCI survivorship planning. Preserve medicine and radiation exposures, major adverse effects and the current contact route. Record new symptoms rather than making independent changes to maintenance or assuming that follow-up ends after one reassuring result.
Research limits: MRD, imaging and trials require the right question
MRD testing should not direct therapy outside trials. NCI MRD limit.
A prognostic association is not automatically a reason to change treatment.
The dated ESMO follow-up framework does not make routine CT obligatory outside trials and discourages PET surveillance. ESMO follow-up context. Symptom-led investigations serve another purpose; the service determines follow-up.
Trials require eligibility assessment, informed consent and monitoring. NCI eligibility; NCI consent and monitoring.
A trial cannot promise personal benefit. Ask which question the study addresses and how its research care differs from available usual care.
This review does not rank medicines independently or adopt manufacturer-supported response or survival claims. Laboratory pathways, animal findings and a molecular test result do not establish a human treatment dose. Country-specific drug access, later guideline updates and the full finances of underlying trials remain open; these limits are recorded rather than replaced with a generic regimen.
Funding and source roles
Research funding at a glance
38 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: NHL symptoms | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL tests | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL treatment | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NCI: infection during cancer treatment | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Reviewed 23 January 2020; dated safety context. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: immunotherapy side effects | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Reviewed 16 February 2023. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: female fertility | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 14 May 2025. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: male fertility | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 14 May 2025. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: follow-up medical care | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 2 December 2024. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: nutrition and cancer claims | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Posted 30 October 2024. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: food and supplement interactions | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 25 April 2024. Page and contributor receipts, and underlying-study finances, are unclosed. PDQ is an information summary, not a treatment guideline. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
| Greenspring Personal Oncology: Seifter service identity | Own page identifies Seifter as oncology lead and lists commercial insurers, Medicare and patient billing. Actual receipts and PDQ payments unknown. | United States; 2328 West Joppa Road, Lutherville, Maryland. | Tier 4 provider promotion; identity only. | D for independent efficacy; C for identity — undated own page. No audited income, manufacturer-payment or disease-page sponsor inferred. |
| WHO lymphoid classification, 2022 | Projekt DEAL open-access support; no interests declared. Separate later coauthor ties do not establish 2022 payments. | International; corresponding contacts UK, US and Germany. | Tier 3 known separately connected coauthor; taxonomy only. | C, provisional — 22 June 2022. Expert taxonomy; receipts unclosed; authorship correction below. |
| WHO classification authorship correction, 2023 | Original correction declares no competing interests; no separate production-money statement found. It corrects authors and affiliations. | International authors; corrected affiliations include Italy and Japan. | Tier 3 financially connected author group; record correction only. | C, provisional — 19 July 2023 full correction read. No treatment or classification outcome inferred from its authorship amendment. |
| Campo et al.: International Consensus Classification, 2022 | NCI/NIAID intramural support; CAC funding refers to 2016 financial record. Authors declare no competing financial interests; allocations unclosed. | International authors; corresponding contacts Barcelona, Spain, and Bethesda, United States. | Tier 3 financially connected funding chain; taxonomy only. | C, provisional — 15 September 2022 issue, online 2 June. Full 25-page original selected sections read; old project chain and supporting studies not cleared. |
| Swerdlow et al.: cited 2016 financial chain | Primary acknowledgments verify charitable/university and drug/test-company support for the Chicago CAC meeting, 31 March–1 April 2014, including Genentech, Incyte and Celgene. | International authors; historical meeting Chicago, United States. | Tier 4 manufacturer-supported historical project; finance only. | D for efficacy; C for historical financial trace — 19 May 2016. Complete primary author copy’s financial footer verified; direct publisher access failed. No inference of identical 2022 sponsors or receipts. |
| ICC erratum record, 2023 | PubMed record identifies the original ICC authors and January 2023 Figure 4 correction; no separate production-funding statement present. | United States; NLM index, Bethesda; original authors international. | Tier 3 administrative record, provisional. | C, provisional — 26 January 2023. Actual record/figure legend read; complete publisher correction body unavailable. No amended image or grading claim adopted. |
| DEAL: publication-payment mechanism | Own description: institutional publication/read fees replace subscription payments; agreements with commercial publishers. Not funding of clinical research itself. | Germany; DEAL Open Access Services, Landsberger Strasse 346, Munich. | Tier 3 institutional financial self-report. | C, provisional — undated body. Publishing access/cost remit favors traceable information; exact 2022 article payer and ledger remain unclosed. |
| ELN 2025: separately dated Hochhaus interests | ELN meeting support, no commercial production funding declared. Hochhaus: Enliven/Incyte/Novartis honoraria and institutional company research, including BMS and Pfizer. | International authors; Hochhaus affiliation Jena, Germany. | Tier 3 connected authors; financial record only. | C, provisional — 11 July 2025 original declarations read. Later relationships are not proof of money for the 2022 classification. |
| Sterling et al.: dated financial declaration, 2024 | Publisher declaration: Sterling had Jerome Greene Foundation support and Medical Logix/Haymarket consulting. Coauthor Paul’s patents/company ties are not assigned to Sterling. | United States; author affiliation Johns Hopkins, Baltimore; publisher MDPI, Switzerland. | Tier 3 known paid education-company consultant; finance only. | C, provisional — 15 October 2024 indexed original declarations read. Direct publisher 429/PMC challenge prevented full read. No inference of PDQ payment or current contracts. |
| Johns Hopkins: Sterling provider profile | Own profile identifies lymphoma care and lists insurer networks, including Aetna and Cigna. Exact clinical, research and PDQ receipts remain unknown. | United States; listed cancer-center location 401 North Broadway Street, Baltimore, Maryland. | Tier 4 provider promotion; identity only. | D for independent efficacy; C for identity — undated own profile. No audited income or personal manufacturer payments inferred; patient ratings excluded. |
| Medical Logix: separate sponsored education project | Own 14 November 2025 course identifies Regeneron educational grant and Medical Logix/Partners joint provision. Not evidence this donor paid Sterling or funded PDQ. | United States educational activity; company headquarters not established by this page. | Tier 4 manufacturer-supported education; finance only. | D for independent efficacy; C for financial self-report — exact project/date checked. Grant size, full company accounts and NHL allocation remain unclosed. |
| Haymarket: educational platform services | Own page markets client activity hosting, promotion, reporting and paid board-review courses. Specific clients, contracts and Sterling receipts unclosed. | Operator serves medical-education clients; exact headquarters not verified in this source. | Tier 4 commercial service promotion; finance only. | D for independent efficacy; C for financial route — undated own body read. Client-service incentives disclosed; engagement claims and clinical outcomes not adopted. |
| NHS: emergency breathlessness | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 30 January 2024; due January 2027. Simplification and source-study/contributor interests remain unclosed. |
| NCI: indolent B-cell PDQ | Public/gift routes below. Leads Seifter/Sterling: provider/education interests separately traced; page/trial receipts unclosed. | United States; NCI. | Tier 3 connected reviewers. | C, provisional — 14 May 2025. Expert synthesis; not an independent trial. |
| NCI dictionary: follicular lymphoma | Public appropriations and gifts documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 context; contributor/trial finance unclosed. | C, provisional — undated short definition; no named author or trial clearance. |
| ESMO follicular guideline, 2021 | No external preparation funding; ESMO central production funds. Dreyling: Roche/Janssen advisory, honoraria and research ties; further author support disclosed. | European authors; ESMO Via Ginevra 4, Lugano, Switzerland. | Tier 3 commercially connected authors; guidance context. | C, provisional — online 26 November 2020; March 2021 issue; clinical update June 2020. Full financial footer read; trial receipts unclosed. |
| ESMO annual report 2023: dated fiscal overview | Membership, meetings, education/training, educational grants and other income. September 2022–July 2023 supporters include Roche, Novartis and Pfizer. No guideline allocation inferred. | Switzerland; ESMO Lugano, separately identified in the guideline/contact record. | Tier 3 institutional financial self-report. | C, provisional — actual 36-page report. Page 34 covers fiscal 2022: 1 May 2022–30 April 2023, based on approved audited statements; underlying ledger/current accounts not read. |
| ESMO 2025 event: office and industry contact | Official event contact offers industry sponsorship opportunities. No fee amount, named guideline sponsor or production allocation established. | Switzerland; Via Ginevra 4, 6900 Lugano. | Tier 3 organizer financial/process self-report. | C, provisional — 2025 event context. Complete official indexed contact text read; direct page redirects. Identity is not a current audited finance ledger. |
| CUH: low-grade lymphoma maintenance clinic | Own provider accounts below; exact leaflet contributors, receipts and original-trial finance unclosed. | United Kingdom; Cambridge University Hospitals, Cambridge. | Tier 2 provisional provider education; context only. | C, provisional — approved 14 January 2025, version 4. Local service instructions; printed date is not review. Efficacy and fixed maintenance schedule excluded. |
| CUH: lymphoma/CLL service introduction | Provider revenue below. Clinical team is named, but leaflet authorship, personal contracts and page allocation remain unclosed. | United Kingdom; Hills Road, Cambridge CB2 0QQ. | Tier 2 provisional provider service context. | C, provisional — approved 19 November 2025, version 2. Local coordination/reputation incentives; universal appointments or delay reassurance excluded. |
| CUH: FY2025–26 audited accounts | NHS commissioners, private/overseas care, research/training, donations and other income; industry/academic partnerships. No leaflet allocation established. | United Kingdom; Cambridge NHS Foundation Trust. | Tier 3 statutory institutional financial report. | B, provisional — actual 197-page FY2025–26 original, notes 2.1–2.3 and partnership sections read. Care, commercial and budget incentives remain. |
| NCI: palliative care alongside cancer treatment | Public appropriations and gifts documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | C, provisional — public accountability and medical review favor accuracy; Reviewed 1 November 2021; author/trial finance unclosed. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: trial consent and safety monitoring | Public appropriations and gifts documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | C, provisional — public accountability and medical review favor accuracy; Undated actual body; contributor and trial finance unclosed. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: trial eligibility | Public appropriations and gifts documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | C, provisional — public accountability and medical review favor accuracy; Updated 8 November 2024; no all-trial financial clearance. Page and contributor receipts, and underlying-study finances, are unclosed. |
Frequently asked questions
Does follicular mean a hair-follicle cancer? No. It refers to microscopic groups of lymphoma cells.
Does everyone without symptoms have to wait? No. Planned monitoring is one selected option. Discuss the actual clinical assessment and available alternatives with your team.
Why can reports use different grading terms? WHO and ICC differ. Preserve the actual system and full diagnosis rather than equating every grade with stage.
Does a high FLIPI score mandate treatment? No. FLIPI does not establish the treatment requirement.
Does a changing node prove transformation? No. A concerning change needs specialist reassessment and may need tissue confirmation.
Can supplements prevent relapse or transformation? No independent benefit is established here; medicine-specific interaction review remains necessary.
Sources and funding notes
Reviewed 4 October 2026. This is a common adult classic-FL guide; separate family entities remain unresolved in the coverage ledger. Current NCI leads Seifter and Sterling and their separately dated financial records were checked. ESMO’s clinical update is June 2020, not a 2026 approval list. Its central production funding and author ties are separate from later institutional support. Historical 2014 CAC finance is not transferred to 2022 classification. Source totals include full linked prose, profiles, references, FAQ questions and uncited repetitions. No numerical outcomes, personal scores, schedules or manufacturer efficacy verdict is supplied.
- NHS: NHL symptoms — Symptoms and referral distinction.
- NHS: NHL tests — Biopsy and possible further investigations.
- NHS: NHL treatment — Selected treatment families and supervised observation.
- NCI: infection during cancer treatment — Urgent infection precautions only.
- NCI: immunotherapy side effects — Healthy-tissue inflammation and reporting only.
- NCI: female fertility — Pre-treatment fertility discussion, without preservation efficacy.
- NCI: male fertility — Pre-treatment fertility discussion, without preservation efficacy.
- NCI: follow-up medical care — Written follow-up plan and treatment record.
- NCI: nutrition and cancer claims — Nutrition versus unproven anticancer diets.
- NCI: food and supplement interactions — Medicine-specific interaction review only.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
- Greenspring Personal Oncology: Seifter service identity — Named reviewer’s private-provider relationship only.
- WHO lymphoid classification, 2022 — Classic FL, optional grading and separate family entities only.
- WHO classification authorship correction, 2023 — Corrected author/institution record only.
- Campo et al.: International Consensus Classification, 2022 — Retained grading versus WHO naming only; not a treatment algorithm.
- Swerdlow et al.: cited 2016 financial chain — Historical funding trace only; no clinical findings.
- ICC erratum record, 2023 — Correction awareness; no figure-derived clinical claim.
- DEAL: publication-payment mechanism — Open-access payment route and operator identity only.
- ELN 2025: separately dated Hochhaus interests — WHO coauthor relationship only; no CML clinical claims.
- Sterling et al.: dated financial declaration, 2024 — Reviewer relationship only; no therapy findings.
- Johns Hopkins: Sterling provider profile — Named reviewer identity and provider relationship only.
- Medical Logix: separate sponsored education project — Consultant-company money route only; unrelated course.
- Haymarket: educational platform services — Consultant-company commercial-service route only.
- NHS: emergency breathlessness — Emergency severe breathing difficulty and sudden confusion.
- NCI: indolent B-cell PDQ — FLIPI, transformation and MRD limits; no outcomes.
- NCI dictionary: follicular lymphoma — Usually indolent B-cell lymphoma and microscopic follicles only.
- ESMO follicular guideline, 2021 — Biopsy, selected care and follow-up context.
- ESMO annual report 2023: dated fiscal overview — Institutional fee/grant and dated industry-support routes only.
- ESMO 2025 event: office and industry contact — Office identity and contemporary sponsorship route only.
- CUH: low-grade lymphoma maintenance clinic — Selected maintenance reviews and communication; not a universal schedule.
- CUH: lymphoma/CLL service introduction — Consultant/nurse coordination only; not a treatment-quality comparison.
- CUH: FY2025–26 audited accounts — Separate provider funding trace; no author or trial clearance.
- NCI: palliative care alongside cancer treatment — Concurrent symptom and practical support only.
- NCI: trial consent and safety monitoring — Consent, monitoring and participant-rights context only.
- NCI: trial eligibility — Trial eligibility only; no promised individual benefit.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.